U.S. CDC Says Flu Strain Resistant To Tamiflu, Leaving Only Relenza
This article was originally published in PharmAsia News
Executive Summary
U.S. authorities have found one of the two main anti-influenza drugs has become ineffective in treating a common flu strain in the United States, leaving only Australia-developed Relenza (zanamivir) as an effective treatment. The U.S. Centers for Disease Control and Prevention said the H5N1 strain circulating across the United States has become resistant to Roche's Tamiflu (oseltamivir). The CDC urged physicians to switch to Relenza, developed by Biota and marketed in the United States by GlaxoSmithKline, or prescribe Tamiflu in combination with ramantadine. (Click here for more)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.